RNA NASDAQ
Atrium Therapeutics, Inc.
1W: +4.3%
1M: -1.2%
3M: -25.6%
YTD: -88.5%
1Y: -82.9%
3Y: +50.7%
5Y: -59.2%
$8.32
+0.27 (+3.35%)
Weekly Expected Move ±5.6%
$7
$8
$8
$9
$9
Credit Risk of going bust: lower than 71% of companies Debt: 1.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.7%), Atrium Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.7M against a stock market value of $142.3M.
Distance to default 7.73 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.7M (short-term plus half of long-term), stock volatility 56.7%; Altman Z'' 2.75. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.7%), Atrium Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.7M against a stock market value of $142.3M.
Distance to default 7.73 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.7M (short-term plus half of long-term), stock volatility 56.7%; Altman Z'' 2.75. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$142.3M
52W Range7.49-16.77
Volume198,570
Avg Volume254,187
Beta0.37
Dividend—
Analyst Ratings
Company Info
CEOKathleen Gallagher
Employees511
SectorHealthcare
IndustryBiotechnology
IPO Date2026-02-27
Websiteatriumtherapeutics.com
10578 Science Center Drive
San Diego, CA 92121
US
San Diego, CA 92121
US
619 876 0700
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Latest News
Atrium Therapeutics (NASDAQ: RNA) lines up $50 million private placement
Atrium Therapeutics raises $50M in private placement
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Younis Husam | F-InKind | 11,216 | $8.95 | 2026-09-18 |
| Hughes Steven George | F-InKind | 21,459 | $8.95 | 2026-09-18 |
| Flanagan W. Michael | F-InKind | 22,812 | $8.95 | 2026-09-18 |
| Boyce Sarah | F-InKind | 126,418 | $8.95 | 2026-09-18 |
| Kenney Stephanie | F-InKind | 2,375 | $8.95 | 2026-09-18 |